Vivos Therapeutics, Inc. Business Acquisition, Pro Forma Revenue
Vivos Therapeutics, Inc. (VVOS) reported Business Acquisition, Pro Forma Revenue of $5.14 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-20.
Financial Statements › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2026-05-20
- Vivos Therapeutics, Inc. business acquisition, pro forma revenue for the quarter ending 2026-03-31 was $5.14M, a 3.78% decline year-over-year.
- Vivos Therapeutics, Inc. business acquisition, pro forma revenue for the quarter ending 2025-12-31 was $4.35M, a 22.71% decline year-over-year.
- Vivos Therapeutics, Inc. business acquisition, pro forma revenue for the quarter ending 2025-09-30 was $6.78M, a 17.25% increase year-over-year.
- Vivos Therapeutics, Inc. business acquisition, pro forma revenue for the quarter ending 2025-06-30 was $5.67M, a 3.13% decline year-over-year.
- Vivos Therapeutics, Inc. business acquisition, pro forma revenue for fiscal 2025 was $21.62M, a 3.77% decline from fiscal 2024.
- Vivos Therapeutics, Inc. business acquisition, pro forma revenue for fiscal 2024 was $22.46M.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 12 month |
|---|---|---|---|---|
| 2026-03-31 | $5.14M 10-Q · filed 2026-05-20 | $9.49M derived: sum of 2 quarters · filed 2026-05-20 | $16.27M derived: sum of 3 quarters · filed 2026-05-20 | $21.94M derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-12-31 | $4.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $11.13M derived: sum of 2 quarters · filed 2026-04-15 | $16.80M derived: sum of 3 quarters · filed 2026-04-15 | $21.62M 10-K · filed 2026-04-15 |
| 2025-09-30 | $6.78M 10-Q · filed 2025-11-19 | $12.45M derived: sum of 2 quarters · filed 2025-11-19 | $17.27M 10-Q · filed 2025-11-19 | $23.41M derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-06-30 | $5.67M 10-Q · filed 2025-08-19 | $11.01M 10-Q · filed 2025-08-19 | $16.63M derived: sum of 3 quarters · filed 2026-05-20 | $22.42M derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-03-31 | $5.34M 10-Q · filed 2026-05-20 | $10.97M derived: sum of 2 quarters · filed 2026-05-20 | $16.75M derived: sum of 3 quarters · filed 2026-05-20 | $22.60M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-12-31 | $5.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $11.41M derived: sum of 2 quarters · filed 2026-04-15 | $17.26M derived: sum of 3 quarters · filed 2026-04-15 | $22.46M 10-K · filed 2026-04-15 |
| 2024-09-30 | $5.79M 10-Q · filed 2025-11-19 | $11.63M derived: sum of 2 quarters · filed 2025-11-19 | $16.84M 10-Q · filed 2025-11-19 | |
| 2024-06-30 | $5.85M 10-Q · filed 2025-08-19 | $11.05M 10-Q · filed 2025-08-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| Tenon Medical, Inc. (TNON) | United States | $0.002B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Profusa, Inc. (PFSA) | United States | $0.002B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |